Early effects of perfluorohexyloctane ophthalmic solution on patient‑reported symptoms of dry eye disease: a prospective, multicenter study
CLOSE
MENU

Early effects of perfluorohexyloctane ophthalmic solution on patient‑reported symptoms of dry eye disease: a prospective, multicenter study


Content provided by Bausch + Lomb Global Medical and Scientific Affairs.

Early effects of perfluorohexyloctane ophthalmic solution on patient‑reported symptoms of dry eye disease: a prospective, multicenter study


Content provided by Bausch + Lomb Global Medical and Scientific Affairs.

Summary

PURPOSE: Perfluorohexyloctane ophthalmic solution (PFHO; MIEBO) is indicated for the treatment of signs and symptoms of dry eye disease (DED). This study evaluated patient-reported symptoms early in treatment with PFHO.

METHODS: This prospective, multicenter, open-label, phase 4 study (NCT06309953) enrolled adults with a history of DED for ≥6 months. PFHO was instilled in both eyes 4 times daily for 14 days. Patients completed early outcome surveys during 4 clinic visits (baseline and days 3, 7, and 14). The primary outcome (symptom severity) is presented separately. Secondary outcomes included patient-reported frequency (percentage of time experiencing) of the most bothersome symptom, awareness of dry eye symptoms, and fluctuations in quality of vision.

RESULTS: The "most bothersome" symptom at baseline (n=99 patients) was eye dryness (28.3%), blurred vision (17.2%), eye irritation (14.1%), light sensitivity (13.1%), eye tiredness (12.1%), burning/stinging (11.1%), or eye itching (4.0%). Mean frequency (percentage of time) experiencing the most bothersome symptom decreased significantly (P<0.0001) from 77.9% at baseline to 46.7% at day 3, 41.3% at day 7, and 34.7% at day 14. Significant (P<0.0001) decreases were also observed in mean frequency of awareness of dry eye symptoms (77.6% at baseline, 39.7% at day 3, 32.6% at day 7, 27.6% at day 14) and fluctuations in quality of vision (62.8% at baseline, 29.8% at day 3, 24.5% at day 7, 19.4% at day 14).

CONCLUSIONS: Early in the course of treatment with PFHO, patients with DED experienced significant reductions in the frequency of dry eye symptoms, including the patient-specific most bothersome symptom.

For More Information:

Get Support

Contact Us

Contact a
Representative

Find My Local Rep link-out icon

Submit a
Medical Inquiry

Complete the Form